{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:58:27Z","timestamp":1783720707474,"version":"3.55.0"},"reference-count":32,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Asthma"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/02770903.2024.2303767","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T13:22:49Z","timestamp":1705670569000},"page":"793-800","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience"],"prefix":"10.1080","volume":"61","author":[{"given":"Y. T.","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Paediatric Respiratory, Royal Hospital for Children, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. C.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Paediatric Respiratory, Royal Hospital for Children, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Langley","sequence":"additional","affiliation":[{"name":"Department of Paediatric Respiratory, Royal Hospital for Children, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Weir","sequence":"additional","affiliation":[{"name":"Department of Paediatric Respiratory, Royal Hospital for Children, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"Dupilumab (Dupixent). Scottish medicines consortium. 2021. https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/dupilumab-dupixent-full-smc2317\/"},{"key":"e_1_3_3_3_1","unstructured":"Dupilumab for treating severe asthma with type 2 inflammation: Guidance. NICE. 2021. https:\/\/www.nice.org.uk\/guidance\/ta751\/chapter\/1-Recommendations"},{"key":"e_1_3_3_4_1","first-page":"102","article-title":"Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents","volume":"160","author":"Sorkness CA","year":"2013","unstructured":"Sorkness CA, Wildfire JJ, Calatroni A, et\u00a0al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immumol Pract. 2013;160:102\u2013110.","journal-title":"J Allergy Clin Immumol Pract"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1321945"},{"key":"e_1_3_3_6_1","unstructured":"Scottish Medicine Consortium 2016. Mepolizumab 100mg powder for solution for injection (NucalaVR). SMC No. (1149\/16)."},{"key":"e_1_3_3_7_1","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: GINA Main Report 2022. 2022. https:\/\/ginasthma.org\/wp-content\/uploads\/2022\/07\/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"e_1_3_3_11_1","unstructured":"GlaxoSmithKline. European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma. London UK: GlaxoSmithKline; 2018. https:\/\/www.gsk.com\/en-gb\/ media\/press-releases\/european-commission-approvesnucala-mepolizumab-for-the-treatment-of-children-withsevere-asthma\/"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.005"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24508"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2019.1579833"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.920066"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.09.008"},{"key":"e_1_3_3_17_1","unstructured":"Scottish Index of Multiple Deprivation 2020v2. 2020. https:\/\/www.gov.scot\/collections\/scottish-index-of-multiple-deprivation-2020\/#revisionnotice"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035005"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200406-710ST"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00080312"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.06.007"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41030-020-00117-6"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.06.042"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01198-9"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2022.2036754"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00419-2021"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.PA2623"},{"key":"e_1_3_3_29_1","unstructured":"European Medicines Agency. Nucala (mepolizumab) - Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.10.007"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2015.OA4792"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2022.2546"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2022.2058"}],"container-title":["Journal of Asthma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02770903.2024.2303767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T17:54:35Z","timestamp":1727200475000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02770903.2024.2303767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/02770903.2024.2303767"],"URL":"https:\/\/doi.org\/10.1080\/02770903.2024.2303767","relation":{},"ISSN":["0277-0903","1532-4303"],"issn-type":[{"value":"0277-0903","type":"print"},{"value":"1532-4303","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijas20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}